Engineering Strategies to Promote Cancer Nanomedicine Performance and Clinical Translation
Time
3:00 PM, June 12, 2026 (Beijing)9:00 AM, June 12, 2026 (Germany)
Contact Us
Email: bmehjournal@sciexplor.comSpeaker
Prof. Twan Lammers
Institute of Experimental Molecular Imaging, University Hospital RWTH Aachen, RWTH Aachen University, Aachen, Germany.
Prof. Twan Lammers obtained a D.Sc. in Radiation Oncology from Heidelberg University in 2008 and a Ph.D. in Pharmaceutical Technology from Utrecht University in 2009. In the same year, he started the Nanomedicine and Theranostics group at RWTH Aachen University. In 2014, he was promoted to full professor of medicine at RWTH Aachen University Clinic. His group aims to individualize and improve disease treatment by combining drug targeting with imaging. To this end, image-guided (theranostic) drug delivery systems are being developed, as well as materials and methods to monitor tumor growth, angiogenesis, inflammation, fibrosis and metastasis. He has received multiple scholarships and awards, including ERC starting, consolidator and proof-of-concept grants, and the CRS Young Investigator and Exceptional Leadership Awards. Prof. Lammers was president of the Controlled Release Society in 2024 and currently serves as secretary of the European Society for Molecular Imaging. He has published over 350 papers (h-index = 103) and has been included in the Clarivate Analytics list of Highly Cited Researchers. He is on the editorial board of more than 10 journals, and acts as Associate Editor for JCR, DDTR and MIB.
Introduction
Nanomedicines are extensively used for cancer therapy. By delivering drug molecules more effectively and more selectively to pathological sites, nanomedicines assist in improving the balance between drug efficacy and toxicity. The tumor accumulation of nanomedicines is traditionally ascribed to the EPR effect, which is highly variable, both in animal models and in patients. To address issues associated with tumor targeting heterogeneity, and to promote cancer nanomedicine clinical translation, we are developing tools and technologies to monitor and modulate tumor-targeted drug delivery. In the present lecture, several of these strategies will be highlighted, including the use of imaging and histopathology biomarkers for patient stratification, and physical, pharmacological and physiological interventions to engineer the tumor microenvironment for better delivery. Together, our work aims to establish rational and realistic ways forward to improve the clinical impact of cancer nanomedicines.
